Advertising policies

  • HOME
  • EDITORIAL POLICY
  • Advertising policies

encephalitis accepts advertisements on the following basis:

  • 1. Eligibility of the advertised products or services
  • All products or services should be safe and reliable and may not cause any harm to the health and welfare of humans. Advertisements may promote information and technologies relevant for authors, editors, reviewers, and readers. Pharmaceutical products may also be considered.
  • 2. Orders
  • Any individuals or organizations who are interested in advertising their products or services in the print copies of the journal are encouraged to contact the Editorial Office. The acceptance of advertisements will be discussed by the editorial board; ultimate approval resides with the publisher.

  • 3. Disclaimer
  • Liability: Neither the publisher nor the editors will be liable for advertisements presented in the journal. In addition, neither can they guarantee the accuracy, completeness, or usefulness of the information provided.

  • Endorsement: The publisher and the editors do not endorse any products or services that are advertised.

  • Disclaimer: Neither the publisher nor the authors will be liable for any content in the advertisements.

  • 767 Refractory neuro-Sweet disease successfully treated with tocilizumab and mycophenolate mofetil
    542 Initial cerebrospinal fluid-restricted oligoclonal bands associate with anti-N-methyl-D-aspartate receptor encephalitis severity: a pilot study
    511 Respiratory virus-related meningoencephalitis in adults
    503 Symptomatic treatments of N-methyl-D-aspartate receptor encephalitis
    462 Anti-N-methyl-D-aspartate receptor encephalitis 8 years after serial herpes simplex virus type 1 and human herpesvirus type 7 encephalitis

    +more

    +more

    • GoogleScholar
    • Similarity Check
    • Crossref Cited-by Linking
    • CrossMark
    • Funder Registry
    • ORCID


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
101, Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea​
Tel: +82-2-2072-0629    Fax: +82-2-765-7920    E-mail: editor@encephalitisjournal.org                

Copyright © 2021 by Korean Encephalitis and Neuroinflammation Society. All rights reserved.

Developed in M2PI

Close layer
prev next